| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis | 12 | 2024 | 1466 | 2.360 |
Why?
|
| Fibroblast Growth Factor 2 | 22 | 2006 | 592 | 1.840 |
Why?
|
| Aortic Valve Stenosis | 14 | 2023 | 2025 | 1.680 |
Why?
|
| Neovascularization, Physiologic | 31 | 2011 | 1377 | 1.620 |
Why?
|
| Calcium Phosphates | 6 | 2016 | 171 | 1.560 |
Why?
|
| Coronary Vessels | 31 | 2019 | 3096 | 1.500 |
Why?
|
| Myocardial Ischemia | 33 | 2014 | 2129 | 1.490 |
Why?
|
| Bioprosthesis | 6 | 2024 | 593 | 1.390 |
Why?
|
| Prosthesis Failure | 5 | 2024 | 1195 | 1.310 |
Why?
|
| Heart Valve Prosthesis Implantation | 13 | 2024 | 1566 | 1.260 |
Why?
|
| Lactic Acid | 6 | 2016 | 1137 | 1.170 |
Why?
|
| Drug-Eluting Stents | 6 | 2019 | 683 | 1.150 |
Why?
|
| Coronary Circulation | 27 | 2019 | 1602 | 1.100 |
Why?
|
| Aortic Valve | 13 | 2024 | 1968 | 1.040 |
Why?
|
| Stents | 15 | 2019 | 3236 | 1.010 |
Why?
|
| Prosthesis Design | 9 | 2024 | 2112 | 1.010 |
Why?
|
| Coronary Restenosis | 5 | 2019 | 396 | 0.870 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2024 | 575 | 0.830 |
Why?
|
| Coronary Disease | 18 | 2010 | 5923 | 0.750 |
Why?
|
| Ultrasonography, Interventional | 7 | 2019 | 1532 | 0.660 |
Why?
|
| Polymers | 4 | 2015 | 1618 | 0.650 |
Why?
|
| Endothelial Growth Factors | 12 | 2003 | 680 | 0.650 |
Why?
|
| Absorbable Implants | 3 | 2016 | 333 | 0.640 |
Why?
|
| Atherectomy, Coronary | 4 | 2011 | 137 | 0.630 |
Why?
|
| Myocardium | 14 | 2013 | 4763 | 0.620 |
Why?
|
| Lymphokines | 11 | 2003 | 911 | 0.620 |
Why?
|
| Angioplasty, Balloon, Coronary | 9 | 2019 | 1727 | 0.600 |
Why?
|
| Swine | 34 | 2016 | 5984 | 0.590 |
Why?
|
| Myocardial Revascularization | 6 | 2005 | 794 | 0.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 25 | 2012 | 3504 | 0.540 |
Why?
|
| Coronary Artery Disease | 16 | 2021 | 6544 | 0.540 |
Why?
|
| Paclitaxel | 3 | 2015 | 1728 | 0.520 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 620 | 0.520 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2023 | 1414 | 0.520 |
Why?
|
| Collateral Circulation | 15 | 2012 | 292 | 0.520 |
Why?
|
| Polyglycolic Acid | 3 | 2014 | 404 | 0.510 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2022 | 452 | 0.500 |
Why?
|
| Coronary Angiography | 23 | 2021 | 4498 | 0.500 |
Why?
|
| Angiogenesis Inducing Agents | 5 | 2006 | 254 | 0.490 |
Why?
|
| Catheterization | 5 | 2011 | 1434 | 0.490 |
Why?
|
| Pericardium | 7 | 2005 | 679 | 0.470 |
Why?
|
| Nanocapsules | 1 | 2015 | 92 | 0.460 |
Why?
|
| Coronary Stenosis | 5 | 2019 | 800 | 0.440 |
Why?
|
| Angioplasty | 2 | 2010 | 357 | 0.440 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 520 | 0.430 |
Why?
|
| Heart Aneurysm | 1 | 2013 | 114 | 0.420 |
Why?
|
| Pericardial Effusion | 3 | 2019 | 246 | 0.420 |
Why?
|
| Myocardial Perfusion Imaging | 6 | 2021 | 669 | 0.410 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2010 | 548 | 0.410 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2022 | 611 | 0.400 |
Why?
|
| Vasodilation | 8 | 2007 | 970 | 0.390 |
Why?
|
| Treatment Outcome | 43 | 2024 | 65236 | 0.380 |
Why?
|
| Peripheral Arterial Disease | 3 | 2014 | 1312 | 0.380 |
Why?
|
| Radiography, Interventional | 3 | 2013 | 1130 | 0.370 |
Why?
|
| Angiogenic Proteins | 3 | 2010 | 101 | 0.360 |
Why?
|
| Aorta, Abdominal | 2 | 2010 | 630 | 0.360 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2019 | 314 | 0.360 |
Why?
|
| Aneurysm, False | 1 | 2013 | 265 | 0.360 |
Why?
|
| Stilbenes | 4 | 2012 | 154 | 0.350 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 108 | 0.340 |
Why?
|
| Foreign-Body Migration | 1 | 2012 | 220 | 0.340 |
Why?
|
| Femoral Artery | 2 | 2011 | 840 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2024 | 1093 | 0.330 |
Why?
|
| Heart Septum | 1 | 2010 | 303 | 0.330 |
Why?
|
| Microcirculation | 9 | 2010 | 1279 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factors | 12 | 2006 | 754 | 0.330 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 934 | 0.320 |
Why?
|
| Iliac Artery | 1 | 2010 | 352 | 0.320 |
Why?
|
| Popliteal Artery | 1 | 2011 | 320 | 0.320 |
Why?
|
| Regional Blood Flow | 3 | 2009 | 1481 | 0.310 |
Why?
|
| Vena Cava Filters | 1 | 2012 | 272 | 0.310 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 7 | 2019 | 1145 | 0.310 |
Why?
|
| Vena Cava, Inferior | 1 | 2012 | 466 | 0.310 |
Why?
|
| Septal Occluder Device | 2 | 2021 | 127 | 0.310 |
Why?
|
| Device Removal | 2 | 2012 | 646 | 0.310 |
Why?
|
| Vascular System Injuries | 1 | 2012 | 246 | 0.310 |
Why?
|
| Ethanol | 4 | 2013 | 1324 | 0.300 |
Why?
|
| Polytetrafluoroethylene | 1 | 2009 | 242 | 0.300 |
Why?
|
| Heart Ventricles | 4 | 2019 | 3831 | 0.290 |
Why?
|
| Laser Therapy | 4 | 2005 | 1109 | 0.290 |
Why?
|
| Natriuretic Agents | 1 | 2008 | 57 | 0.290 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2008 | 1339 | 0.290 |
Why?
|
| Injections | 5 | 2005 | 839 | 0.290 |
Why?
|
| Thrombectomy | 2 | 2002 | 682 | 0.280 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2003 | 1657 | 0.280 |
Why?
|
| Biocompatible Materials | 3 | 2014 | 1683 | 0.280 |
Why?
|
| Arteritis | 1 | 2009 | 159 | 0.270 |
Why?
|
| Angina Pectoris | 6 | 2019 | 957 | 0.270 |
Why?
|
| Renal Artery Obstruction | 1 | 2008 | 233 | 0.260 |
Why?
|
| Ischemia | 2 | 2008 | 1923 | 0.260 |
Why?
|
| Vasodilator Agents | 5 | 2010 | 988 | 0.260 |
Why?
|
| Gene Transfer Techniques | 2 | 2001 | 1216 | 0.260 |
Why?
|
| Echocardiography | 5 | 2023 | 5042 | 0.260 |
Why?
|
| Coronary Artery Bypass | 7 | 2008 | 2188 | 0.250 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 1110 | 0.250 |
Why?
|
| Myocardial Infarction | 9 | 2010 | 11506 | 0.240 |
Why?
|
| Syncope | 1 | 2008 | 429 | 0.240 |
Why?
|
| Pulmonary Edema | 1 | 2008 | 412 | 0.240 |
Why?
|
| Ventricular Function, Left | 6 | 2012 | 3930 | 0.230 |
Why?
|
| Heart Block | 1 | 2006 | 391 | 0.230 |
Why?
|
| Hypercholesterolemia | 5 | 2012 | 1148 | 0.220 |
Why?
|
| Atrial Septum | 2 | 2022 | 61 | 0.220 |
Why?
|
| Coronary Aneurysm | 1 | 2006 | 233 | 0.220 |
Why?
|
| Humans | 107 | 2024 | 766011 | 0.220 |
Why?
|
| Male | 78 | 2024 | 363808 | 0.220 |
Why?
|
| Drug Delivery Systems | 4 | 2006 | 2206 | 0.220 |
Why?
|
| Sirolimus | 1 | 2010 | 1544 | 0.210 |
Why?
|
| Instillation, Drug | 1 | 2003 | 32 | 0.210 |
Why?
|
| Animals | 56 | 2016 | 168721 | 0.210 |
Why?
|
| Heart Atria | 3 | 2019 | 1363 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2019 | 2965 | 0.210 |
Why?
|
| Coronary Thrombosis | 2 | 2002 | 440 | 0.200 |
Why?
|
| Leg | 1 | 2008 | 1108 | 0.200 |
Why?
|
| Saphenous Vein | 3 | 2002 | 520 | 0.200 |
Why?
|
| Skin Transplantation | 1 | 2007 | 1098 | 0.200 |
Why?
|
| Regeneration | 1 | 2010 | 1517 | 0.190 |
Why?
|
| Heart Diseases | 4 | 2022 | 2821 | 0.190 |
Why?
|
| Exercise Therapy | 1 | 2008 | 937 | 0.190 |
Why?
|
| Aortic Aneurysm | 1 | 2006 | 649 | 0.190 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 1429 | 0.190 |
Why?
|
| Materials Testing | 3 | 2015 | 867 | 0.190 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1377 | 0.190 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2003 | 268 | 0.190 |
Why?
|
| Electrophysiology | 2 | 2023 | 1263 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2005 | 1463 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 2025 | 0.170 |
Why?
|
| Dyspnea | 1 | 2008 | 1352 | 0.170 |
Why?
|
| Fibroblast Growth Factors | 2 | 2003 | 871 | 0.170 |
Why?
|
| Aged | 43 | 2024 | 171233 | 0.170 |
Why?
|
| Myocardial Reperfusion | 3 | 2013 | 338 | 0.170 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2016 | 959 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2023 | 5304 | 0.160 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 580 | 0.160 |
Why?
|
| Pericardiectomy | 1 | 2019 | 46 | 0.160 |
Why?
|
| Recurrence | 4 | 2024 | 8505 | 0.160 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 78 | 0.160 |
Why?
|
| Hemodynamics | 10 | 2017 | 4190 | 0.160 |
Why?
|
| Foramen Ovale, Patent | 1 | 2022 | 211 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 1736 | 0.160 |
Why?
|
| Drug Implants | 2 | 2015 | 230 | 0.160 |
Why?
|
| Disease Models, Animal | 17 | 2012 | 18289 | 0.160 |
Why?
|
| Polyesters | 3 | 2015 | 373 | 0.160 |
Why?
|
| Infusions, Intravenous | 7 | 2008 | 2229 | 0.160 |
Why?
|
| Needles | 1 | 2002 | 460 | 0.160 |
Why?
|
| Myocardial Contraction | 4 | 2002 | 1516 | 0.150 |
Why?
|
| Activities of Daily Living | 4 | 2020 | 2415 | 0.150 |
Why?
|
| Swine, Miniature | 8 | 2014 | 971 | 0.150 |
Why?
|
| Female | 63 | 2023 | 396159 | 0.150 |
Why?
|
| Fistula | 1 | 2019 | 212 | 0.150 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 2224 | 0.150 |
Why?
|
| Fluoroscopy | 3 | 2013 | 947 | 0.150 |
Why?
|
| Delirium | 2 | 2020 | 1704 | 0.140 |
Why?
|
| Bronchial Fistula | 1 | 2018 | 82 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2021 | 20676 | 0.140 |
Why?
|
| Mitral Valve | 5 | 2023 | 1476 | 0.140 |
Why?
|
| Drainage | 2 | 2019 | 1180 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2014 | 8103 | 0.140 |
Why?
|
| Gastric Fistula | 1 | 2018 | 73 | 0.140 |
Why?
|
| Pilot Projects | 3 | 2023 | 8733 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 3 | 2010 | 594 | 0.140 |
Why?
|
| Catheter Ablation | 3 | 2008 | 2788 | 0.140 |
Why?
|
| Follow-Up Studies | 16 | 2023 | 39226 | 0.140 |
Why?
|
| Heart | 6 | 2012 | 4418 | 0.140 |
Why?
|
| Endothelium, Vascular | 7 | 2012 | 4423 | 0.130 |
Why?
|
| Thrombosis | 1 | 2010 | 2956 | 0.130 |
Why?
|
| Pacemaker, Artificial | 1 | 2022 | 827 | 0.130 |
Why?
|
| Hemoptysis | 1 | 2018 | 150 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2019 | 5997 | 0.130 |
Why?
|
| Rats | 7 | 2014 | 23702 | 0.130 |
Why?
|
| Gastroscopy | 1 | 2018 | 211 | 0.130 |
Why?
|
| Catheters | 1 | 2019 | 426 | 0.130 |
Why?
|
| Extremities | 1 | 2001 | 870 | 0.130 |
Why?
|
| Models, Anatomic | 1 | 2019 | 677 | 0.120 |
Why?
|
| Carotid Artery, Internal | 1 | 2018 | 442 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 2630 | 0.120 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 15403 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 422 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 10389 | 0.120 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 59526 | 0.120 |
Why?
|
| Random Allocation | 4 | 2011 | 2394 | 0.120 |
Why?
|
| Angiostatins | 3 | 2010 | 64 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 2729 | 0.120 |
Why?
|
| Autoradiography | 3 | 2005 | 723 | 0.120 |
Why?
|
| Tissue Distribution | 3 | 2005 | 2268 | 0.110 |
Why?
|
| Retreatment | 2 | 2018 | 597 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 413 | 0.110 |
Why?
|
| Metals | 2 | 2011 | 710 | 0.110 |
Why?
|
| Atrial Appendage | 1 | 2018 | 284 | 0.110 |
Why?
|
| Skin | 1 | 2007 | 4479 | 0.110 |
Why?
|
| Endothelial Cells | 6 | 2007 | 3584 | 0.110 |
Why?
|
| Time Factors | 12 | 2019 | 40117 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 834 | 0.110 |
Why?
|
| Middle Aged | 37 | 2019 | 223058 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 6545 | 0.100 |
Why?
|
| Prospective Studies | 15 | 2023 | 54818 | 0.100 |
Why?
|
| Heparin | 5 | 2005 | 1632 | 0.100 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 280 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2000 | 1164 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 2046 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2018 | 909 | 0.100 |
Why?
|
| Wine | 1 | 2012 | 172 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 6 | 2002 | 219 | 0.100 |
Why?
|
| Risk Factors | 10 | 2023 | 74870 | 0.090 |
Why?
|
| Endostatins | 2 | 2008 | 167 | 0.090 |
Why?
|
| Transplantation, Autologous | 2 | 2010 | 2126 | 0.090 |
Why?
|
| Anesthesia | 1 | 2022 | 1590 | 0.090 |
Why?
|
| Phlebography | 1 | 2012 | 329 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 1030 | 0.090 |
Why?
|
| Alcoholic Beverages | 1 | 2012 | 265 | 0.090 |
Why?
|
| Recombinant Proteins | 5 | 2005 | 6489 | 0.090 |
Why?
|
| Time | 2 | 2002 | 550 | 0.090 |
Why?
|
| Naproxen | 1 | 2010 | 99 | 0.090 |
Why?
|
| Aortography | 1 | 2012 | 425 | 0.090 |
Why?
|
| Tissue Transplantation | 1 | 2010 | 128 | 0.090 |
Why?
|
| Acute Disease | 4 | 2010 | 7238 | 0.090 |
Why?
|
| Neointima | 1 | 2010 | 133 | 0.080 |
Why?
|
| Neuropeptide Y | 1 | 2010 | 194 | 0.080 |
Why?
|
| Ligation | 2 | 2007 | 444 | 0.080 |
Why?
|
| Arteries | 3 | 2003 | 1123 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 14751 | 0.080 |
Why?
|
| Quality of Life | 5 | 2023 | 13470 | 0.080 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 855 | 0.080 |
Why?
|
| Solubility | 1 | 2010 | 1077 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2010 | 361 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15803 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 938 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2010 | 318 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 1407 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2018 | 1272 | 0.080 |
Why?
|
| Oxidative Stress | 4 | 2012 | 3140 | 0.080 |
Why?
|
| Technetium Tc 99m Mertiatide | 1 | 2008 | 22 | 0.070 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 14645 | 0.070 |
Why?
|
| Exercise Test | 4 | 2005 | 2184 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2012 | 5019 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3674 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13639 | 0.070 |
Why?
|
| Surface Properties | 1 | 2010 | 1146 | 0.070 |
Why?
|
| Hypertension | 1 | 2008 | 8627 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2023 | 8040 | 0.070 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 1108 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15887 | 0.070 |
Why?
|
| Nitroprusside | 3 | 2006 | 271 | 0.070 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2009 | 263 | 0.060 |
Why?
|
| Thoracotomy | 2 | 2005 | 370 | 0.060 |
Why?
|
| Counterpulsation | 1 | 2005 | 16 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 548 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2006 | 693 | 0.060 |
Why?
|
| Angioplasty, Laser | 1 | 2005 | 19 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2008 | 1382 | 0.060 |
Why?
|
| Radionuclide Imaging | 2 | 2008 | 1984 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 685 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 147 | 0.060 |
Why?
|
| Intermittent Claudication | 1 | 2008 | 310 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 788 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 561 | 0.060 |
Why?
|
| Equipment Design | 2 | 2004 | 3487 | 0.060 |
Why?
|
| Adenosine Diphosphate | 3 | 2006 | 419 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2012 | 36543 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2004 | 648 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 416 | 0.060 |
Why?
|
| Pressure | 1 | 2008 | 1168 | 0.060 |
Why?
|
| Heart Arrest, Induced | 1 | 2006 | 358 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 5753 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1670 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2010 | 2074 | 0.060 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 344 | 0.060 |
Why?
|
| Nitroglycerin | 2 | 2003 | 331 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 3183 | 0.060 |
Why?
|
| Endocardium | 1 | 2005 | 249 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2012 | 707 | 0.060 |
Why?
|
| Chronic Disease | 6 | 2010 | 9355 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2008 | 899 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2019 | 1834 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 911 | 0.050 |
Why?
|
| Double-Blind Method | 5 | 2005 | 12433 | 0.050 |
Why?
|
| Sulfonamides | 2 | 2010 | 1981 | 0.050 |
Why?
|
| Kinetics | 1 | 2010 | 6261 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 20125 | 0.050 |
Why?
|
| Adenosine | 3 | 2003 | 806 | 0.050 |
Why?
|
| Hexuronic Acids | 2 | 1999 | 144 | 0.050 |
Why?
|
| Glucuronic Acid | 2 | 1999 | 148 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2014 | 1957 | 0.050 |
Why?
|
| Xiphoid Bone | 1 | 2002 | 10 | 0.050 |
Why?
|
| Exercise Tolerance | 2 | 2005 | 841 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 4278 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 318 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2008 | 10429 | 0.050 |
Why?
|
| Angiography | 1 | 2008 | 1599 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2017 | 10086 | 0.050 |
Why?
|
| Electrocardiography | 3 | 2006 | 6404 | 0.050 |
Why?
|
| Gene Expression Regulation | 5 | 2012 | 11888 | 0.050 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2004 | 348 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1318 | 0.050 |
Why?
|
| Radiography | 4 | 2014 | 6938 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2022 | 5947 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 728 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 1028 | 0.050 |
Why?
|
| Research Design | 2 | 2011 | 6207 | 0.050 |
Why?
|
| Receptors, Mitogen | 1 | 2001 | 61 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2005 | 514 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2023 | 379 | 0.050 |
Why?
|
| Alginates | 2 | 1999 | 247 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2009 | 2002 | 0.050 |
Why?
|
| Muscle Development | 1 | 2003 | 258 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2006 | 5343 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2269 | 0.040 |
Why?
|
| Canada | 2 | 2019 | 2119 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2002 | 682 | 0.040 |
Why?
|
| Prognosis | 6 | 2021 | 29915 | 0.040 |
Why?
|
| Medicare | 1 | 2018 | 6821 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 324 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2010 | 2031 | 0.040 |
Why?
|
| Sus scrofa | 2 | 2012 | 430 | 0.040 |
Why?
|
| Pyrroles | 1 | 2006 | 1119 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 898 | 0.040 |
Why?
|
| Punctures | 1 | 2021 | 372 | 0.040 |
Why?
|
| Safety | 3 | 1999 | 1158 | 0.040 |
Why?
|
| Forecasting | 3 | 2006 | 2938 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2006 | 851 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 438 | 0.040 |
Why?
|
| Arterioles | 2 | 2013 | 251 | 0.040 |
Why?
|
| Boston | 2 | 2002 | 9341 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 1999 | 152 | 0.040 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 1999 | 53 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 2699 | 0.040 |
Why?
|
| Body Surface Potential Mapping | 1 | 2000 | 228 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2008 | 12768 | 0.040 |
Why?
|
| Prevalence | 3 | 2019 | 15833 | 0.040 |
Why?
|
| Veins | 1 | 2003 | 769 | 0.040 |
Why?
|
| Delayed-Action Preparations | 2 | 1999 | 967 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 758 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2003 | 1688 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2020 | 41652 | 0.040 |
Why?
|
| Drug Compounding | 1 | 1999 | 235 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2001 | 361 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2009 | 2859 | 0.040 |
Why?
|
| Drug Carriers | 2 | 1999 | 697 | 0.040 |
Why?
|
| France | 1 | 2019 | 495 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2000 | 703 | 0.040 |
Why?
|
| Cell Survival | 1 | 2007 | 5746 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1601 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2011 | 1643 | 0.040 |
Why?
|
| Tachyphylaxis | 1 | 1997 | 54 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2003 | 1622 | 0.030 |
Why?
|
| Amiodarone | 1 | 1999 | 216 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 512 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 15647 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 1997 | 6838 | 0.030 |
Why?
|
| Models, Animal | 1 | 2003 | 2120 | 0.030 |
Why?
|
| Models, Cardiovascular | 3 | 2012 | 979 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1717 | 0.030 |
Why?
|
| Gene Expression | 3 | 2005 | 7583 | 0.030 |
Why?
|
| Syndrome | 1 | 2002 | 3269 | 0.030 |
Why?
|
| Heart Rate | 3 | 2010 | 4203 | 0.030 |
Why?
|
| Perfusion | 2 | 2010 | 1408 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1998 | 941 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2001 | 784 | 0.030 |
Why?
|
| Apoptosis | 3 | 2010 | 9511 | 0.030 |
Why?
|
| Placebos | 1 | 1999 | 1659 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1999 | 771 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 1997 | 513 | 0.030 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2014 | 92 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1996 | 176 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 1670 | 0.030 |
Why?
|
| Proteoglycans | 1 | 1997 | 793 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2008 | 636 | 0.030 |
Why?
|
| Capillaries | 2 | 2010 | 751 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2475 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2002 | 8531 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2006 | 731 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2011 | 8279 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2018 | 1263 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 10731 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2012 | 91 | 0.030 |
Why?
|
| Caspases | 2 | 2006 | 880 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 456 | 0.020 |
Why?
|
| Thallium Radioisotopes | 2 | 2002 | 138 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2003 | 192 | 0.020 |
Why?
|
| Nitric Oxide | 3 | 2006 | 2143 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7845 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3251 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2002 | 185 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2001 | 3404 | 0.020 |
Why?
|
| Embolism | 1 | 1994 | 403 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2003 | 260 | 0.020 |
Why?
|
| Patient Selection | 2 | 2000 | 4257 | 0.020 |
Why?
|
| Singapore | 1 | 2011 | 297 | 0.020 |
Why?
|
| Outpatients | 1 | 1999 | 1593 | 0.020 |
Why?
|
| Hospital Costs | 1 | 1997 | 957 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2019 | 2277 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2010 | 223 | 0.020 |
Why?
|
| Nitroarginine | 2 | 2001 | 66 | 0.020 |
Why?
|
| Adult | 9 | 2022 | 223109 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2010 | 317 | 0.020 |
Why?
|
| Signal Transduction | 4 | 2010 | 23590 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2010 | 396 | 0.020 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 5188 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2005 | 4863 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 434 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 5782 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 658 | 0.020 |
Why?
|
| Cardiology | 1 | 2000 | 1702 | 0.020 |
Why?
|
| Collagen Type XVIII | 1 | 2008 | 52 | 0.020 |
Why?
|
| Cathepsin L | 1 | 2008 | 69 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2008 | 71 | 0.020 |
Why?
|
| RNA | 1 | 1998 | 2716 | 0.020 |
Why?
|
| Plasminogen | 1 | 2008 | 144 | 0.020 |
Why?
|
| Curriculum | 1 | 2022 | 3782 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2012 | 881 | 0.020 |
Why?
|
| Cattle | 2 | 2004 | 3800 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 2 | 2002 | 1006 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 2470 | 0.020 |
Why?
|
| Rabbits | 1 | 2014 | 4733 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3710 | 0.020 |
Why?
|
| Cathepsins | 1 | 2008 | 242 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 4961 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 3527 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 1248 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11036 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 1415 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 655 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 3691 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2006 | 64 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9595 | 0.020 |
Why?
|
| Neoplasms | 1 | 1996 | 22350 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 462 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 51 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 24299 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 589 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 542 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 64 | 0.020 |
Why?
|
| United States | 4 | 2019 | 72914 | 0.020 |
Why?
|
| Anthracenes | 1 | 2005 | 82 | 0.020 |
Why?
|
| Butadienes | 1 | 2005 | 107 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 3618 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2005 | 3418 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2006 | 183 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13271 | 0.020 |
Why?
|
| Age Factors | 1 | 2002 | 18384 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 900 | 0.020 |
Why?
|
| Survival Rate | 2 | 1998 | 12821 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2021 | 81522 | 0.010 |
Why?
|
| Europe | 1 | 2011 | 3427 | 0.010 |
Why?
|
| Registries | 1 | 2021 | 8321 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 1225 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2000 | 8927 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 12123 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 455 | 0.010 |
Why?
|
| Reference Values | 1 | 2011 | 4910 | 0.010 |
Why?
|
| Metformin | 1 | 2012 | 904 | 0.010 |
Why?
|
| Kidney | 1 | 1999 | 7073 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 143 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2006 | 594 | 0.010 |
Why?
|
| Heart Failure | 1 | 2008 | 11839 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 2057 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2011 | 4015 | 0.010 |
Why?
|
| Mice | 2 | 2008 | 81786 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 201 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 610 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 423 | 0.010 |
Why?
|
| Macrophages | 1 | 1997 | 5771 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 1546 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 601 | 0.010 |
Why?
|
| Epoprostenol | 1 | 2003 | 246 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 521 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1885 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 1529 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 6307 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16707 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 1332 | 0.010 |
Why?
|
| Stroke Volume | 3 | 2000 | 5596 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2006 | 1090 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 361 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 21507 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2003 | 591 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 3824 | 0.010 |
Why?
|
| Nitriles | 1 | 2005 | 981 | 0.010 |
Why?
|
| Regression Analysis | 2 | 2001 | 6321 | 0.010 |
Why?
|
| DNA Probes | 1 | 2001 | 541 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 331 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2010 | 8537 | 0.010 |
Why?
|
| Imidazoles | 1 | 2005 | 1164 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2010 | 4020 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 1409 | 0.010 |
Why?
|
| Disease Progression | 1 | 1996 | 13615 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 1489 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 330 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2005 | 18972 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3108 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1998 | 181 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 1166 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5877 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 1150 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 898 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 1959 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 639 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 3584 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 975 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 2667 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1998 | 158 | 0.010 |
Why?
|
| Syndecans | 1 | 1997 | 75 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2454 | 0.010 |
Why?
|
| Cholesterol | 1 | 2006 | 2898 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 1997 | 163 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 1639 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 2087 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2002 | 660 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1999 | 582 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 5744 | 0.010 |
Why?
|
| Hypotension | 1 | 2002 | 886 | 0.010 |
Why?
|
| Echo-Planar Imaging | 1 | 2000 | 649 | 0.010 |
Why?
|
| Rest | 1 | 2000 | 942 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 1731 | 0.010 |
Why?
|
| Microspheres | 1 | 1997 | 773 | 0.010 |
Why?
|
| Biosensing Techniques | 1 | 2000 | 641 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9439 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 14061 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3804 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4563 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 2880 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 2889 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1998 | 893 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 1885 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2000 | 1405 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2846 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 88804 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 5787 | 0.010 |
Why?
|
| Serotonin | 1 | 1997 | 1047 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1999 | 1471 | 0.010 |
Why?
|
| Creatinine | 1 | 1998 | 1917 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 13402 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2000 | 2475 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 17595 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 4912 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3715 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 2136 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15541 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 5990 | 0.000 |
Why?
|
| Health Status | 1 | 2002 | 4083 | 0.000 |
Why?
|
| Hospitalization | 1 | 2006 | 10807 | 0.000 |
Why?
|
| Cell Movement | 1 | 1997 | 5190 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 5528 | 0.000 |
Why?
|